Abnormality of Insulin Binding and Receptor Phosphorylation in an Insulin-resistant Melanoma Cell Line

HANS U. HARING, MORRIS F. WHITE, C. RONALD KAHN, MASATO KASUGA, VILMA LAURIS, ROBERT FLEISCHMANN,* MARILYN MURRAY,* and JOHN PAWELEK*
E. P. Joslin Research Laboratory, Joslin Diabetes Center, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215; and *Department of Dermatology, Yale Medical School, New Haven, Connecticut 06510

ABSTRACT The insulin receptor possesses an insulin-stimulated tyrosine-kinase activity; however, the significance of receptor phosphorylation in terms of the binding and signaling function of the receptor is unclear. To help clarify this problem, we have studied insulin binding and receptor phosphorylation in a Cloudman S91 melanoma cell line and two of its variants: the wild type (1A) in which insulin inhibits cell growth, an insulin-resistant variant (111) in which insulin neither stimulates or inhibits growth, and a variant (46) in which insulin stimulates cell growth.

$^{125}$I-insulin binding to intact cells was similar for the wild-type 1A and insulin-stimulated variant 46. The insulin-resistant variant 111, in contrast, showed ~30% decrease in insulin binding. This was due to a decrease of receptor affinity with no major difference in receptor number. When the melanoma cells were solubilized in 1% Triton X-100 and the insulin receptor was partially purified by chromatography on wheat germ agglutinin-agarose, a similar pattern of binding was observed.

Phosphorylation was studied by incubation of the partially purified receptor with insulin and [γ-$^{32}$P]ATP, and the receptor was identified by immunoprecipitation and NaDodSO$_4$ PAGE. Insulin stimulated phosphorylation of the 95,000-mol-wt β-subunit of the receptor in all three cell types with similar kinetics. The amount of $^{32}$P incorporated into the β-subunit in the insulin-resistant cell line 111 was ~50% of that observed with the two other cell lines. This difference was reflected throughout the entire dose-response curve (10$^{-9}$ M to 10$^{-6}$ M). Qualitatively similar results were obtained when phosphorylation was studied in the intact cell. Peptide mapping of the β-subunit using tryptic digestion and reverse-phase high-performance liquid chromatography column separation indicated three sites of phosphorylation in receptor from the wild type and variant 46, but only two major sites of phosphorylation of variant 111. These data suggest that the insulin-resistant variant melanoma 111 possesses a specific defect in the insulin receptor which alters both its binding and autophosphorylation properties, and also suggests a possible role of receptor phosphorylation in both the binding and the signaling function of the insulin receptor.

Insulin stimulates phosphorylation of the 95,000-mol-wt (β) subunit of the insulin receptor. This phenomenon, first observed in hepatoma cells and lymphocytes (1), has been shown to occur in all cell types containing insulin receptors (2-12). Insulin receptor phosphorylation can be demonstrated in intact cells (1, 2, 6, 7) and in cell-free systems using both partially purified receptor (2-11) and highly purified receptor preparations (5). In broken cell systems, the insulin receptor kinase is tyrosine specific, whereas in whole cells, insulin stimulates phosphorylation at both tyrosine and serine residues (2, 3). Evidence has been presented using ATP-affinity labeling that the protein kinase activity that catalyzes the phosphorylation is present in the β-subunit of the receptor itself (12).

The role of receptor autophosphorylation in the binding and signaling function of the receptor is not known. One
approach to understanding the role of this process is to study
receptor phosphorylation in cells with altered insulin re-
sponse. Cloudman S91 melanoma cells and its variants are a
good system for such studies. Pawelek and co-workers have
shown that insulin inhibits growth of the wild-type melanoma
cell (13). Thus, it has been possible to select several variants
from this cell line with altered insulin response. In this paper,
we have characterized insulin binding and receptor phos-
phorylation in the wild-type Cloudman S91 melanoma (A)
and two variants: one (111) in which insulin has no effect on
growth and one (46) in which insulin has a growth-stimulating
effect (14, 15). We find that receptor from the insulin-resistant
cell type 111 shows decreased autophosphorylation and de-
creased receptor affinity. By peptide mapping, the decreased
phosphorylation appears to be due to a loss of one of three
sites of phosphorylation. These data suggest that receptor phos-
phorylation plays a role in both the binding and the
signaling function of the insulin receptor and that the mutant
111 possesses a defect which alters these functions.

MATERIALS AND METHODS

Materials

Porcine insulin (lot UMN95AN) was purchased from Eli Lilly and Co.
(Indianapolis, IN); [3H]orthophosphate, [γ-32P]ATP, and Triton X-100 were
purchased from New England Nuclear (Boston, MA). Aprotinin, phenylmethyl-
lysulfonyl fluoride, and N-acetyl-o-glucosamine were obtained from Sigma
Chemical Co. (St. Louis, MO); wheat germ agglutinin coupled to agarose was
from Vector Laboratories, Inc. (Burlingame, CA); and TPCK-treated trypsin
was from Worthington Biochemical Corp. (Freehold, NJ). All reagents for
NaDodSO4 PAGE were from Bio-Rad Laboratories (Richmond, CA).

Biologically active [3H]insulin was prepared by the lactoperoxidase method
and the A(1)isoforms were isolated by high performance liquid chromatography (HPLC),
resulting in a specific activity of ~360 Ci/g (16).

Cell Culture

Melanoma cells were cultured in modified Ham's F10 medium with 5%
feetal calf serum in monolayer in plastic dishes in a humidified atmosphere of
5% CO2/95% O2 at 37°C (16). Medium was changed every 3rd d and cells were
split when confluence was reached. EDTA (1 mM) was used for cell detachment.
Confluent cells were used for binding and phosphorylation experiments. Be-
cause insulin inhibits growth of the wild-type A3 cells (13), the insulin-resistant
111 and insulin-dependent 46 variants could be selected from cells treated with
either 0.1% BSA and 25 mM HEPES buffer (pH 7.4) or 1% BSA and 25 mM
NaODsO4 (pH 7.4). The variant colonies were isolated and cloned in medium containing
25 mM HEPES buffer (pH 7.4) containing 1% Triton X-100, 10 mM
sodium pyrophosphate, 100 mM NaF, and 4 mM EDTA, the bound material
was eluted with buffer supplemented with 0.3 M NaN3/glucomannan. With
other cell types, this has been shown to result in a 20-fold purification and a
100% recovery of the insulin receptor (17). The eluted fractions were precipi-
tated with sera from patients which contain autoantibodies against the insulin
receptor (B-8, 1:30 dilution) or normal pooled serum as previously described
(1). With the latter, a 1:100 dilution of sera from patients with insulin resistant
syndrome was used.

Determination of Rates of Proliferation

To determine rates of proliferation under various culture conditions, (2 x
10⁶) cells were inoculated in 25-cm² Corning tissue culture flasks (Corning
Glass Works, Corning, NY) in 4 ml medium, and medium was changed three
times per week. Triplicate cultures were harvested and counted in a Coulter
Counter (Coulter Electronics, Inc., Hialeah, FL) every 2 or 3 d over a 2-wk
period. Variation within triplicate samples was ± 15%. The generation time
was determined from the rate of division in log phase from the following
equation: generation time = [0.69 (H)]/ln (C2/C0), where H is the time in
hours between counting the initial cell number (C0) and the final cell number
(C2). Generation time was determined using only the linear portion of a growth
curve.

Receptor Phosphorylation in Intact Cells

Cells were plated in 10-cm tissue culture dishes. After reaching confluence,
cells were washed twice with phosphate-free Krebs-Ringer bicarbonate buffer
containing 0.1% BSA and 25 mM HEPES, pH 7.4, and incubated at 37°C in
this buffer with 0.125 μCi/ml of [3H]orthophosphate in a humidified atmos-
phere containing 7% CO2. After 120 min, insulin (final concentration 5 x 10⁻⁷
M) was added to half of the flasks and incubation was continued for 20 min at
37°C. The reaction was stopped by addition of cold Krebs-Ringer bicarbonate
buffer containing 10 mM sodium pyrophosphate, 100 mM NaF, and 4 mM
EDTA, and the cells were washed with this "stopping buffer.

The [3H]orthophosphate-labeled cells were solubilized in 25 mM HEPES buffer
(pH 7.4) containing 1% Triton X-100, phenylmethylsulfonyl fluoride (2 mM)
Aprotinin (1 TIU/ml), 10 mM sodium pyrophosphate, 100 mM NaF, and 4 mM
EDTA at 4°C for 30 min. Insoluble material was removed by centrifugation
at 200,000 g for 60 min, and the supernatants were applied to columns
containing wheat germ agglutinin coupled to agarose. After extensive washing
with 25 mM HEPES buffer (pH 7.4) containing 0.1% Triton X-100, 10 mM
sodium pyrophosphate, 100 mM NaF, and 4 mM EDTA, the bound material
was eluted with buffer supplemented with 0.3 M NaN3/glucomannan. With
other cell types, this has been shown to result in a 20-fold purification and a
100% recovery of the insulin receptor (17). The eluted fractions were precipi-
tated with sera from patients which contain autoantibodies against the insulin
receptor (B-8, 1:30 dilution) or normal pooled serum as previously described
(1). With the latter, a 1:100 dilution of sera from patients with insulin resistant
syndrome was used.

Preparation of Solubilized Wheat Germ
Purified Receptor In Vivo

Preparation of solubilized receptor and purification over wheat germ was
performed as described above except that the cells were grown in normal
medium until extraction of the receptors. NaF, sodium pyrophosphate, EDTA,
and insulin were omitted from the solubilization buffer. For phosphorylation
studies, aliquots of the eluted fractions from the lectin column were incubated
with or without insulin at room temperature for 1 h followed by incubation
with [γ-32P]ATP 50-100 μM in 100 mM HEPES buffer, pH 7.4, containing 10
mM MgCl2, and 2 mM MnCl2 at 4°C or 22°C for 5-60 min. The phosphorylation
reaction was stopped at 4°C by addition of NaODsO4 (200 mM), sodium pyro-
phosphate (10 mM), EDTA (5 mM), and ATP (5 mM). The insulin receptor
subunits were identified by immunoprecipitation with antibodies against insulin
receptor followed by NaODsO4 PAGE under reducing conditions and auto-
radiography as described above.

Insulin Binding

IMACT CELLS: 36-48 h hours before an experiment, cells were detached
in a saline solution containing EDTA (0.2 mg/ml) and transferred to six-well
tissue culture dishes with 1.2-1.4 x 10⁵ cells per well. For the binding experi-
ments, cell incubations were carried out in a modified F10 medium without
glucose containing 20 mM HEPES at pH 7.8 and 1% bovine serum albumin
(buffered medium). Confuent monolayer cultures of cells (~2 x 10⁶ cells/35-
mm plate) were incubated with 1 ml buffered medium (pH 7.8) containing
1-3 x 10⁻¹⁴ M-[125I]insulin and various concentrations of unlabeled insulin for 3
h at 4°C. At the end of the reaction, cells were washed three times with 2 ml of cold PBS, solubilized in 1 ml of 0.01% SDS and the radioactivity was quantitated in a Tracer 1190 autogamma counter (TM
Analytic, Elk Grove Village, IL).

BINDING TO SOLUBILIZED RECEPTOR: Solubilized and wheat germ-
purified receptor was prepared as described above. Aliquots of wheat germ
eluate containing between 10 and 15 μg protein were incubated with [125I]insulin
(1-10 nM) and various concentrations of unlabeled insulin overnight at 4°C
in a medium of 150 mM NaCl and HEPES 25 mM at pH 7.4. Separation of
the free and receptor-bound insulin was then performed by precipitation of
the solubilized receptor with polyethylene glycol (12.5% final concentration) as
described earlier (19), using human γ-globulin (0.1 mg) as carrier protein.
The protein pellets were washed once with polyethylene glycol and counted in a
Tracer 1190 autogamma counter.
**Tryptic Peptide Mapping by HPLC**

Fixed and dried polyacrylamide gel fragments containing the phosphorylated receptor (located by autoradiography) were washed for 12 h at 37°C with 20 ml of 10% methanol. The absorbent paper was removed from the gel fragment. The gel was dried at 70°C for 60 min and rehydrated in 2 ml of 50 mM NH4HCO3 containing 100 μg of TPCK-treated trypsin (Worthington Biochemical Corp.). This mixture was incubated for 24 h at 37°C, the gel fragment was removed and the supernatant was clarified by centrifugation and lyophilized. The residue was dissolved in 25–50 μl of 0.1% trifluoroacetic acid. The phosphopeptides were separated using a Waters HPLC system (Waters Instruments, Inc., Rochester, MN) equipped with a μBondapak C18 reversed-phase column (20). Phosphopeptides applied to the column were eluted at a flow rate of 1 ml/min. The column was washed for 5 min with 0.05% trifluoroacetic acid in water and then the peptides were eluted with a gradient of acetonitrile also containing 0.05% trifluoroacetic acid increasing at a rate of 1% per min. Radioactivity in 0.5–1.0-ml fractions eluted from the reversed-phase column was measured in 5 ml of scintillation mixture.

**RESULTS**

**Insulin Effect on Cell Growth**

The effect of insulin on growth rates of the wild type Cloudman S91 melanoma cells and the two variants is shown in Fig. 1. Insulin (~7 × 10^-7 M) inhibited the growth of the wild-type cells; the generation time for these cells increased from 35 to 86 h in the presence of insulin. This effect of insulin has been previously shown to be mediated via the insulin receptor based on dose-response curves for insulin analogues and the ability of antibody to the insulin receptor to inhibit this effect (13–15). By contrast, insulin stimulated growth of the variant cell line 46 and the generation time decreased from 103 to 47 h. A similar picture was observed (Fig. 2B), i.e., binding was slightly lower in the extract of 111 and slightly higher in the extract of 46 than in the wild type when expressed per microgram of protein. Thus, there was no apparent difference in the yield of receptor after solubilization and wheat germ purification among the three cell types, and the differences in the binding present in the three cell lines was retained after solubilization and partial purification.

Analysis of insulin binding for all three cell types yielded curvilinear Scatchard plots (Fig. 3). Quantitative analysis of the Scatchard plots were performed using a negative cooperative model (21) and an M-lab computer modeling program. Using this model, the decrease in binding in the resistant cell line was due to a decrease in affinity with no change in receptor concentration (84.5 vs. 95 fmol/mg of protein). Receptor concentration was also similar in the insulin-dependent cell line 46. Thus, all three melanoma lines exhibit similar receptor numbers, but the insulin-resistant line 111 exhibits decreased receptor affinity, and the insulin-dependent line 46 exhibits a slightly increased receptor affinity.

**Receptor Phosphorylation in Variant and Wild-Type Cells**

In vitro autophosphorylation of the 95,000-M, subunit of the insulin receptor was studied after wheat germ purification of the receptor. As in other cell lines, when equal amounts of the partially purified receptor isolated from each of the cell...
lines were incubated in vitro with $[^{32}\text{P}]$ATP, Mn$^{++}$, and insulin, and the proteins analyzed by immunoprecipitation and NaDodSO$_4$ gel electrophoresis, autophosphorylation of the receptor was observed (Fig. 4). In all three cell lines, the major phosphorylated protein had a $M_r = 95,000$, the position previously shown to contain the $\beta$-subunit of the insulin receptor. Further evidence that this was the $\beta$-subunit of the receptor was the finding that the protein was specifically precipitated by antireceptor antibody (Fig. 5, lanes A, C, E, G, I, K vs. B, D, F, H, J, L) and that the phosphorylation was stimulated by insulin (Fig. 5, lanes C, G, K vs. A, E, I). Quantitatively, insulin receptor from the insulin-resistant cell line 111 was less heavily phosphorylated than the receptor from the two insulin-sensitive cell lines when studied at equal protein concentration (Figs. 4 and 5, lane G vs. C and K). Two kinds of evidence indicate that the lower phosphorylation of the 95,000-$M_r$ band in 111 cells was not caused by a less efficient immunoprecipitation of the receptor in this cell line. First, when antibodies to the insulin receptor raised in rabbits were used for immunoprecipitation instead of human autoantibodies, a similar decrease in phosphorylation was seen. Secondly, in experiments in which the partially purified receptor was not immunoprecipitated, but subjected directly to electrophoresis after phosphorylation, the insulin-dependent phosphorylation of the 95,000-$M_r$ band was decreased in line 111 when compared with the other two cell lines (data not shown). As shown in Fig. 3, when insulin was removed for the culture medium 24 h before study, type 46 cells had a similar number of insulin receptors as the wild-type melanoma, and under these conditions, this cell line showed the same intensity of autophosphorylation as the wild-type cell. If insulin was not removed from the culture media, type 46 cells exhibited $\sim$50% loss of receptors due to down-regulation (data not shown) and also a less intense phosphorylation of the $\beta$-subunit than the wild-type IA melanoma (Fig. 5, lane C vs.

HARING ET AL. Insulin Binding and Receptor Phosphorylation 903

FIGURE 2 Competition for $^{125}$I-insulin binding by unlabeled insulin in intact melanoma cells (A) and solubilized receptors partially purified by wheat germ affinity chromatography (B). Data on the wild type IA are shown by $\bullet$, variant 111 by $\circ$, and variant 46 by $\times$.

FIGURE 3 Scatchard plot of insulin binding to intact melanoma cells. The data are those in Fig. 2, and the code is the same. The Scatchard plots were fit using a negative cooperative model (21) and an M-lab computer program.
Characterization of the Autophosphorylation

Fig. 6 shows the time course of receptor phosphorylation in all three cell types. In this in vitro system, all cell types exhibited sigmoidal kinetics of phosphorylation with an initial lag period and a half time of ~20 min. The decreased phosphorylation of receptor from line 111 was evident at all time points studied. The exact significance of the sigmoidal kinetics is unknown at present, but may suggest a positive cooperativity of the phosphorylation process in the solubilized system due to activation of the receptor kinase by the autophosphorylation, as suggested by Rosen et al. (22).

Quantitation of phosphorylation was performed by densitometric scanning of gels. An effect of insulin was detectable at $10^{-9}$ M in all three cell types and half-maximal stimulation was observed between $10^{-9}$ and $10^{-8}$ M (Fig. 7). This is similar to the dose-response in other cell lines and is similar to the displacement curves of insulin binding in Fig. 2. A decrease in the phosphorylation of the receptor in type 111 was observed in six separate experiments at all insulin concentrations. At concentrations of insulin which saturate all receptors, this decrease averaged 50% (Table I). In general, receptors from type 46 cells exhibited slightly higher levels of insulin-stimulated phosphorylation than receptor from wild type (Table I).

Phosphopeptide Analysis

In an effort to determine if the decreased phosphorylation in the 111 insulin-resistant variant was due to a general or specific modification in this receptor, the sites of phosphorylation were analyzed by digesting the phosphorylated receptor.
and is expressed in relative values. The receptor was
otheritol, analyzed in NaDodSO4 polyacrylamide (7.5%), and au-
the \( \beta \)-subunit of the insulin receptor in the cell-free system. The
M for 1 h at room temperature. The phosphorylation assay was
carried out for the time intervals shown in the figure at 4°C as
described in the Materials and Methods section. The receptor was

**FIGURE 6**

Time course of incorporation of \( ^{32}P \) from \( \gamma^{32}P \)ATP into
the \( \beta \)-subunit of the insulin receptor in the cell-free system. The
insulin receptors were partially purified from wild-type melanoma
\( 1A \) cells (○), type 46 cells (x), and type 111 (O). Receptors from all
three cell types (~20 \( \mu \)g) were preincubated with insulin ~5 \( \times \) 10\( ^{-7} \)
M for 1 h at room temperature. The phosphorylation assay was

with trypsin and subjecting the resultant phosphopeptides to
analysis by HPLC on a reversed-phase column. In the wild-
type \( 1A \) cells, three phosphopeptides were identified (Fig. 8,
top), consistent with our previous observation that in vitro
there are multiple sites of autophosphorylation in the insulin
receptor (20). A similar pattern was observed in the insulin-
sensitive variant 46 (Fig. 8, bottom). By contrast, the insulin-
resistant variant 111 appeared to be lacking a discrete peak at
position 2, whereas peaks 1 and 3 were unchanged (Fig. 8, center).
Due to the low amount of radioactivity in each peak,
statistical evaluation was impossible; however, similar HPLC
elution patterns were observed in two separate experiments.

**Receptor Phosphorylation in Intact Cells**

Insulin receptor phosphorylation was also studied in the intact cell. To reduce the background of other phosphoproteins in these experiments, a rabbit serum containing antibodies to the insulin receptor was used for precipitation or the wheat germ-purified labeled material was first precipitated with control serum and the supernatant was then precipitated with serum containing antireceptor antibody. An autoradiogram of such an experiment is shown in Fig. 9. Although the labeling of the receptor was low in intact cells as compared with the in vitro assays, in both the wild-type \( 1A \) cell and type 46 phosphorylation of the \( \beta \)-subunit of the insulin receptor was detectable after insulin stimulation. By contrast, little or no phosphorylation of the 95,000-Mr subunit of the insulin receptor could be detected in type 111 cells.

**DISCUSSION**

Although the exact mechanism of insulin action remains
unknown, insulin has been shown to affect the state of phos-
phorylation of a variety of cellular proteins and enzymes (23–
26). This protein modification has been suggested to play a
role in the post receptor transmission of the insulin signal.
Recently, we have presented evidence that the insulin receptor
is a protein kinase, and have proposed that receptor-induced
phosphorylation may be an early step in the signal transmis-
son process (1–5). These findings have been confirmed and
extended using receptors from a wide variety of tissues (5–
12).

Insulin-receptor phosphorylation occurs at multiple sites
(2). The receptor itself is tyrosine-specific protein kinase which
will autophosphorylate, as well as catalyze the incorporation
of phosphate into the tyrosine residues of artificial substrates
in in vitro systems (5, 22, 27). In the intact cell, there is also
phosphorylation of the \( \beta \)-subunit of the receptor on serine and
threonine residues (2) suggesting that in vivo the receptor

In the present study, we have shown that an insulin-resistant
melanoma cell line possesses an altered insulin receptor,
which is defective both in its affinity for insulin and its
autophosphorylation properties. In the cell-free system,
phosphorylation of partially purified receptor from insulin-resistant
melanoma cells is ~50% lower than the phosphorylation
of receptor from the insulin-sensitive cell lines at maximal
insulin concentration. This difference cannot be explained by
differences in recovery, differences in immunoprecipitation
or the different binding characteristics of the receptor from this
cell line. Although insulin-receptor affinity is decreased
by ~30%, decreased binding is seen only at low insulin
concentrations; at saturating insulin concentrations the number
of occupied receptors per milligram of protein is equal in
all three cell types. Even at saturating insulin concentrations,
however, phosphorylation is reduced ~50%.

The view that the reduced phosphorylation is not caused
by a lower receptor number is also supported by two other
types of experimental evidence. In the experiment shown in
Fig. 5, receptors from down-regulated type 46 cells, which show ~50% reduction in number were used. Phosphorylation
of the insulin receptor of the down-regulated 46 cells was
lower than in the 95,000-Mr, band of \( 1A \), but was still higher
than that of the \( \beta \)-subunit of type \( 111 \) cells. Thus, it seems
likely that the decreased phosphorylation observed with the
insulin-resistant cell 111 is a reflection of a defect in the
receptor itself.

Peptide mapping of the phosphorylated receptor reveals
three sites of autophosphorylation in the wild-type and insu-
lin-sensitive cells, whereas in the insulin-resistant mutant one
is missing. This would suggest a defect in the receptor as a
substrate for autophosphorylation rather than as a kinase.
This is supported by a preliminary observation that the insulin
receptor from 111 cells is as active as receptor from the wild
type in catalyzing phosphorylation of an exogenous substrate
such as histone (White, M. F., and C. R. Kahn; unpublished
observation). Whether there is actually a modification in
sequence of the receptor or in some other factor that alters
accessibility of site 2 remains to be determined. It is also
possible that there is microheterogeneity of receptors, and that
the lack of site 2 reflects a loss of a particular receptor form.

Recent studies with epidermal growth factor (EGF) (28–
30), platelet-derived growth factor (PDGF) (31, 32) and RNA-
FIGURE 7 (left) Autoradiogram showing the dose response of the insulin effect on incorporation of \(^{32P}\) from \([\gamma-\text{32P}]\)ATP into the \(\beta\)-subunit of the insulin receptor in a cell free system. Insulin receptors were partially purified from wild-type melanoma 1A cells (four left lanes), from cell type 111 (four middle lanes), and from cell type 46 (four right lanes). Receptors (~20 \(\mu\)g) were preincubated for 1 h at room temperature with insulin in the concentrations indicated for each lane in the figure. The phosphorylation assay was performed as described in Materials and Methods with ~15-20 \(\mu\)g protein and 0.1 mCi \([\gamma-\text{32P}]\)ATP per lane at 4°C for 60 min. Immunoprecipitation was performed with antireceptor antibody containing serum (1:300). The immunoprecipitates were reduced with 0.1 M dithiothreitol and analyzed in NaDodSO\(_4\)-7.5% PAGE. (right). Dose response of insulin action on phosphorylation of the insulin receptor 95,000-M\(_{r}\) subunit from wild-type 1A (\(\bullet\)), type 111 (\(\circ\)), and type 46 (\(\times\)) as determined by densitometry scanning in arbitrary units.

TABLE 1
Comparison of Binding and Autophosphorylation Characteristics in the Three Melanoma Cell Lines

| Cell line | Tracer binding | Receptor affinity | Receptor capacity | Receptor phosphorylation |
|-----------|----------------|-------------------|-------------------|--------------------------|
| 1A        | 100            | 100               | 100               | 100                      |
| 111       | 63             | 79                | 90                | 49 ± 7                   |
| 46        | 125            | 156               | 84                | 137 ± 18                 |

The binding values are derived from the data shown in Figs. 2 and 3 and represent the mean of three experiments. The phosphorylation data are the mean of seven in vitro experiments using four separate receptor preparations. All data were expressed as the percent of control observed in the parental cell line (1A) which was taken as 100%. The values of phosphorylation are expressed as the mean ± SEM.

Tumor viruses (33–38) suggest that phosphorylation of proteins on tyrosine is associated with the regulation of cell proliferation. Both EGF and PDGF stimulate tyrosine-directed phosphorylation of their own plasma membrane receptors. Both growth factors have also been shown to stimulate the phosphorylation of exogenous substrates via their receptor-associated kinases. In the case of EGF, a series of mutants of the A431 cells in which the effect of EGF on growth is altered have been studied to determine if there were also altered hormone effect on phosphorylation of the receptor (39). Unlike our study, however, all of the variants that showed decreased phosphorylation also exhibited a comparable decrease in receptor number.

Insulin has been shown to be a growth-regulating hormone in a number of cell types (40–43). The observation that insulin, like EGF and PDGF, acts on tyrosine phosphorylation is consistent with the concept that tyrosine-specific kinases may be important in regulation of cell growth. The coincidence of a defect in insulin-receptor phosphorylation with a loss of the effect of insulin on growth in the 111 variant further supports this concept.

Another result of the present study is the finding that the reduced receptor phosphorylation present in 111 cells is associated with a reduced receptor affinity. Whether this is a result of the same modification of the receptor that results in altered phosphorylation activity is not clear. Certainly, it is also possible that autophosphorylation may play a role in modulation of the binding activity of the receptor affinity. The data in the melanoma cells would suggest that receptors in a high autophosphorylation state also possess a high affinity for hormone. This hypothesis is also supported indirectly from studies in adipocytes and hepatocytes (43–46). In these cells, the rate of insulin dissociation decreases within seconds after insulin is bound to the cell. This rapid change appears to be independent of internalization and results from a change in the receptor from a low to a high affinity state. This change of affinity does not occur in ATP-depleted cells (46), and it is possible that insulin-induced autophosphorylation is the underlying process of this insulin-induced change from a low to a high affinity state of the receptor.

Another point worth noting is the difference between the in vitro and in vivo studies. The phosphorylation defect of the receptor of type 111 can be clearly demonstrated in the
in vitro system, whereas its demonstration in the intact cell was more difficult to interpret because of the low intensity of the 95,000-M, band. In two experiments with the intact 111 cells in which a double immunoprecipitation was performed to reduce background, there was no detectable insulin effect consistent with an abnormality of receptor phosphorylation in this cell line. Phosphorylation of the receptor in intact cells involves both a tyrosine kinase (the receptor) and an unknown serine kinase (2). The latter is not present on the in vitro system (3) and, therefore, a defect in the intrinsic insulin receptor kinase could be more or less apparent in the intact cell than in the partially purified system depending on the activity of this serine kinase.

In summary, the insulin-resistant melanoma 111 contains a mutant insulin receptor, which is altered in both its auto-phosphorylation and insulin binding activity. The data of this study support the concept that receptor phosphorylation is involved in insulin signal transmission. Furthermore, the data suggest the possibility that receptor phosphorylation also may influence the binding affinity of the insulin receptor.

Dr. Haring is a recipient of a fellowship of the Deutsche Forschungsgemeinschaft. This work was supported in part by grants AM 31036 and AM 33201 from the National Institutes of Health.

Received for publication 1 March 1983, and in revised form 24 May 1984.

REFERENCES

1. Kasuga, M., F. A. Karlsson, and C. R. Kahn. 1982. Insulin stimulates the phosphorylation of the 95,000-Dalton subunit of its own receptor. Science (Wash. DC). 215:185–187.
2. Kasuga, M., X. Zick, D. L. Blithe, F. A. Karlsson, H. U. Haring, and C. R. Kahn. 1982. Insulin stimulation of phosphorylation of the β-subunit of the insulin receptor. J. Biol. Chem. 257:9891–9894.
3. Kasuga, M., X. Zick, D. L. Blithe, M. Crettaz, and C. R. Kahn. 1983. Insulin stimulates tyrosine phosphorylation on the insulin receptor in a “cell-free” system. Nature (Lond.). 298:667–669.
4. Zick, Y., M. Kasuga, C. R. Kahn, and J. Roth. 1983. Characterization of insulin-mediated phosphorylation of the insulin receptor in a cell-free system. J. Biol. Chem. 258:75–80.
5. Kasuga, M., Y. Fujita-Yamaguchi, D. L. Blithe, and C. R. Kahn. 1983. Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. Proc. Natl. Acad. Sci. USA. 80:2137–2141.
6. Van Obberghen, E., and A. Kowalski. 1982. Phosphorylation of the hepatic insulin receptor. FEBS (Fed. Eur. Biochem. Soc.) Lett. 143:179–182.
7. Haring, H. U., M. Kasuga, and C. R. Kahn. 1982. Insulin receptor phosphorylation in intact adipocytes and in a cell-free system. Biochem. Biophys. Res. Commun. 108:1538–1543.
8. Persuttielli, L. M., S Ganguly, C. R. Smith, M. H. Cobb, C. S. Rubin, and O. Rosen. 1982. Insulin activates a tyrosine-specific protein kinase in extracts of 3T3-L1 adipocytes and human placenta. Proc. Natl. Acad. Sci. USA. 79:6792–6796.
9. Machicao, F. T., T. Urinow, and P. H. Wedland. 1982. Phosphorylation-dephosphorylation of purified insulin receptor from human placenta. FEMS (Fed. Eur. Biochem. Soc.) Lett. 149:96-100.

10. Antov, J. R., A. Nemesoff, P. J. Blackshear, M. W. Piero, and R. Osathanondh. 1982. Insulin stimulated tyrosine phosphorylation of the insulin in detergent extracts of human placental membranes. J. Biol. Chem. 257:15162-15166.

11. Zick, Y., J. Whitaker, and J. Roth. 1983. Insulin stimulated phosphorylation of its own receptor; activation of a tyrosine-specific protein kinase that is tightly associated with the receptor. J. Biol. Chem. 258:3431-3434.

12. Roth, R. A., and D. I. Cassell. 1983. Insulin receptor: evidence that it is a protein kinase. Science (Wash. DC.). 219:299-301.

13. Pawelek, J., M. Sassone, N. Koch, G. Christie, R. Halaban, J. Hendee, A. B. Lerner, and J. Varga. 1978. Melanoma cells resistant to inhibition of growth by melanocyt stimulating hormone. Proc. Natl. Acad. Sci. USA. 75:96-100.

14. Pawelek, J., M. Murray, and R. Fleischmann. 1982. Growth of cells in hormonally defined media. Cold Spring Harbor Conf. Cell Proliferation. 9:911-920.

15. Kahn, R., M. Murray, and J. Pawelek. 1980. Inhibition of proliferation of Cloudman S91 melanoma cells by insulin and characterization of some insulin-resistant variants. J. Cell. Physiol. 103:109-119.

16. Markussen, J., and V. D. Lener. 1980. The application of HPLC to the analysis of radioiodinated tracers of glucagon and insulin. J. Chromatogr. Structure and Function of Insulin and Related Hormones. D. Brandenburg and A. Wollmer, editors. de Gruyter Co., Berlin and New York. 160-168.

17. Heslo, A. A., L. C. Harrison, and J. Roth. 1981. Binding of insulin receptors to lectins: evidence for common carbohydrate determinants on several membrane receptors. Biochemistry. 20:3385-3393.

18. Laemmli, U. K. 1970. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature (Lond.). 227:680-695.

19. Harrison, L. C., and A. Itin. 1980. Purification of the insulin receptor from human placenta by chromatography on immobilized wheat germ lectin and receptor antibody. J. Biol Chem. 255:10607-1072.

20. White, M. F., H. U. Haring, M. Kasuga, and C. R. Kahn. 1981. Kinetic properties and sites of autophosphorylation of the partially purified insulin receptor from hepatoma cells. J. Biol. Chem. 259:255-264.

21. De Meyts, P., A. R. Bianco, and J. Roth. 1976. Site-site interactions among insulin receptors. J. Biol Chem. 251:1877-1888.

22. Rosen, O. M., R. Herrera, Y. Olowe, L. M. Petruzelli, and M. H. Cobb. 1983. Proc. Natl. Acad. Sci. USA. 80:1237-1240.

23. Cortis, J. D., C. O. Breschick, R. L. Alexander, and E. G. Krebs. 1972. Adenosine 3':5'-monophosphate dependent protein kinase from adipose tissue. J. Biol Chem. 247:3736-3742.

24. Benjamin, W. B., and N. L. Clayton. 1978. Action of insulin and catecholamines on the phosphorylation of proteins associated with the cytosol, membranes, and "fat cake" of rat fat cells. J. Biol Chem. 253:1700-1709.

25. Avrich, J. G. R. Leon, and D. B. Martin. 1976. Effects of epinephrine and insulin on adipose metabolism in adipocytes. J. Biol Chem. 251:151-1515.

26. Smith, C. J., R. J. Wekselov, J. B. Warren, C. S. Rubin, and O. M. Rosen. 1979. Insulin stimulated tyrosine phosphorylation in ST3 L1 preadipocytes. Proc. Natl. Acad. Sci. USA. 76:2725-2729.

27. Kasuga, M., Y. Fujita-Tamaoichi, D. L. Bicke, M. F. White, and C. R. Kahn. 1983. Characterization of the insulin receptor-kinase isolated from human placental membranes. J. Biol Chem. 258:10973-10980.

28. Carpenter, G. L., K. King, and S. Cohen. 1979. Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor. J. Biol. Chem. 254:4884-4891.

29. Usdin, J., and S. Cohen. 1980. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 255:8363-8365.

30. Pike, L. J., R. Gallis, J. E. Canestili, P. Bornstein, and E. G. Krebs. 1982. Epidermal growth factor stimulates the phosphorylation of synthetic tyrosine containing peptides by A-431 cell membranes. Proc. Natl. Acad. Sci. USA. 79:1443-1447.

31. Ek, B., W. Westermark, A. Wastenson, and C. H. Heldin. 1982. Stimulation of tyrosine specific phosphorylation by platelet-derived growth factor. Nature (Lond.). 295:419-420.

32. Nishimura, J., J. S. Huang, and T. F. Dewel. 1982. Platelet-derived growth factor stimulates tyrosine-specific protein kinase activity in Swiss mouse 3T3 cell membranes. Proc. Natl. Acad. Sci. USA. 79:4303-4307.

33. Collett, M. S., A. F. Perchino, and R. L. Erikson. 1980. Avian sarcoma virus transforming protein, pp60src, shows protein kinase activity specific for tyrosine. Nature (Lond.). 285:167-169.

34. Collett, M. S., E. Erikson, A. F. Perchino, J. S. Brugge, and R. L. Erikson. 1979. Abnormal cell protein similar in structure and function to the avian sarcoma. Proc. Natl. Acad. Sci. USA. 76:3159-3163.

35. Hunter, T., and B. M. Sefton. 1980. The transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA. 77:1311-1315.

36. Levinson, A. D., H. Oppermann, H. E. Varums, and J. M. Bishop. 1980. The purified product of the transforming gene of avian sarcoma virus phosphorylates tyrosine.

37. Oppermann, H., A. D. Levinson, H. E. Varums, L. Levintow, and J. M. Bishop. 1979. Uninfected vertebrate cells containing a protein that is closely related to the product of the avian sarcoma virus transforming gene (src). Proc. Natl. Acad. Sci. USA. 76:1804-1808.

38. Zager, O. N., A. Dacuga, and D. Baltimore. 1980. Abelson murine leukemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature (Lond.). 283:826-831.

39. Zager, J. E., J. E. Kudlow, C. S. Lazar, and G. N. Gill. 1982. Altered epidermal growth factor (EGF)-stimulated protein kinase activity in variant A431 cells with altered growth responses to EGF. Proc. Natl. Acad. Sci. USA. 79:2754-2758.

40. Lieberman, J., and P. Owe. 1959. Growth factors for mammalian cells in culture. J. Cell Biol. 234:2754-2758.

41. Kooz, J. W., and M. Iwashita. 1981. Insulin as a potent, specific growth factor in a rat hepatoma cell line. Science (Wash. DC.). 219:947-949.

42. Rechler, M., J. M. Podolsky, L. D. Goldfine, and C. Wells. 1976. DNA synthesis in human fibroblasts: stimulation by insulin and by nonsuppressible insulin-like activity (NSILA-S). J. Cell. Enzynol. 39:512-521.

43. King, G. L., and C. R. Kahn. 1981. Non-parallel evolution of metabolic and growth promoting functions of insulin. Nature (Lond.). 292:644-646.

44. Kahn, C. R., and K. L. Baird. 1978. The fate of insulin bound on adipocytes. Proc. Natl. Acad. Sci. USA. 75:4303-4307.

45. Margulies, D. H., D. C. Brocks, E. A. Siess, and W. Kemmler. 1980. Early events in insulin binding and insulin action in fat cells and hepatoites. In Chemistry, Structure and Function of Insulin and Related Hormones. D. Brandenburg and A. Wollmer, editors. de Gruyter Co., Berlin and New York. 469-474.

46. Haring, H. U., D. C. Brocks, and W. Kemmler. 1981. Coupling of insulin binding and glucose transport in isolated fat cells. Am. J. Physiol. 240:E556-E565.